These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8330012)

  • 1. Plasminogen activation activity of urokinase determined via a cascade enzymatic reaction system.
    Lee WC; Chuang CY; Chang RM
    Biochem Mol Biol Int; 1993 Apr; 29(6):1039-46. PubMed ID: 8330012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor XIIa is a kinetically favorable plasminogen activator.
    Schousboe I; Feddersen K; Røjkjaer R
    Thromb Haemost; 1999 Sep; 82(3):1041-6. PubMed ID: 10494761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of cell viability dramatically elevates cell surface plasminogen binding and activation.
    O'Mullane MJ; Baker MS
    Exp Cell Res; 1998 Jul; 242(1):153-64. PubMed ID: 9665813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype.
    Swiercz R; Wolfe JD; Zaher A; Jankun J
    Clin Cancer Res; 1998 Apr; 4(4):869-77. PubMed ID: 9563880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis.
    He Y; Liu XD; Chen ZY; Zhu J; Xiong Y; Li K; Dong JH; Li X
    Clin Cancer Res; 2007 Jun; 13(11):3115-24. PubMed ID: 17545513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.
    Liu JN; Tang W; Sun ZY; Kung W; Pannell R; Sarmientos P; Gurewich V
    Biochemistry; 1996 Nov; 35(45):14070-6. PubMed ID: 8916892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD; Tomaso H; Mengele K; Schilling D; Bayer C; Stadler P; Schmitt M; Molls M
    Oncol Rep; 2007 May; 17(5):1259-68. PubMed ID: 17390074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic studies of the urokinase catalysed conversion of NH2-terminal lysine plasminogen to plasmin.
    Christensen U; Müllertz S
    Biochim Biophys Acta; 1977 Jan; 480(1):275-81. PubMed ID: 137749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urokinase-type plasminogen activator.
    Crippa MP
    Int J Biochem Cell Biol; 2007; 39(4):690-4. PubMed ID: 17118695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
    Perides G; Noring R; Klempner MS
    Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assembly of urokinase receptor-mediated plasminogen activation complexes involves direct, non-active-site interactions between urokinase and plasminogen.
    Ellis V; Whawell SA; Werner F; Deadman JJ
    Biochemistry; 1999 Jan; 38(2):651-9. PubMed ID: 9888805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity.
    Stillfried GE; Saunders DN; Ranson M
    Breast Cancer Res; 2007; 9(1):R14. PubMed ID: 17257442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent antitumor activity of a urokinase-activated engineered anthrax toxin.
    Liu S; Aaronson H; Mitola DJ; Leppla SH; Bugge TH
    Proc Natl Acad Sci U S A; 2003 Jan; 100(2):657-62. PubMed ID: 12525700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mice lacking tissue plasminogen activator and urokinase plasminogen activator genes show attenuated matrix metalloproteases activity after sciatic nerve crush.
    Siconolfi LB; Seeds NW
    J Neurosci Res; 2003 Nov; 74(3):430-4. PubMed ID: 14598319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of the urokinase plasminogen activation system in angiogenesis].
    Smolarz B; Błasiak J; Kulig A
    Postepy Biochem; 2000; 46(3):261-70. PubMed ID: 11138429
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.